Northwest Biotherapeutics Inc (NWBO)
0.519
-0.08
(-13.50%)
USD |
OTCM |
Mar 28, 16:00
Northwest Biotherapeutics Enterprise Value: 752.65M for March 27, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
March 27, 2024 | 752.65M |
March 26, 2024 | 670.54M |
March 25, 2024 | 649.12M |
March 22, 2024 | 613.48M |
March 21, 2024 | 616.04M |
March 20, 2024 | 619.37M |
March 19, 2024 | 640.79M |
March 18, 2024 | 656.26M |
March 15, 2024 | 669.35M |
March 14, 2024 | 669.35M |
March 13, 2024 | 687.20M |
March 12, 2024 | 705.05M |
March 11, 2024 | 697.91M |
March 08, 2024 | 713.38M |
March 07, 2024 | 723.02M |
March 06, 2024 | 724.80M |
March 05, 2024 | 705.76M |
March 04, 2024 | 727.42M |
March 01, 2024 | 737.77M |
February 29, 2024 | 690.77M |
February 28, 2024 | 681.37M |
February 27, 2024 | 679.82M |
February 26, 2024 | 674.59M |
February 23, 2024 | 686.93M |
February 22, 2024 | 696.81M |
Date | Value |
---|---|
February 21, 2024 | 698.10M |
February 20, 2024 | 752.76M |
February 16, 2024 | 699.74M |
February 15, 2024 | 695.75M |
February 14, 2024 | 713.26M |
February 13, 2024 | 686.46M |
February 12, 2024 | 698.69M |
February 09, 2024 | 720.43M |
February 08, 2024 | 734.11M |
February 07, 2024 | 753.23M |
February 06, 2024 | 760.46M |
February 05, 2024 | 708.68M |
February 02, 2024 | 685.29M |
February 01, 2024 | 669.42M |
January 31, 2024 | 685.17M |
January 30, 2024 | 710.44M |
January 29, 2024 | 727.48M |
January 26, 2024 | 740.42M |
January 25, 2024 | 737.36M |
January 24, 2024 | 755.70M |
January 23, 2024 | 758.05M |
January 22, 2024 | 770.51M |
January 19, 2024 | 754.29M |
January 18, 2024 | 767.45M |
January 17, 2024 | 728.66M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
103.89M
Minimum
Mar 18 2020
1.873B
Maximum
May 05 2022
684.23M
Average
719.84M
Median
Dec 23 2021
Enterprise Value Benchmarks
NovaBay Pharmaceuticals Inc | 0.5012M |
Palatin Technologies Inc | 16.33M |
iBio Inc | 21.57M |
Theriva Biologics Inc | -19.95M |
Ampio Pharmaceuticals Inc | -5.467M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -18.92M |
Revenue (Quarterly) | 0.445M |
Total Expenses (Quarterly) | 15.59M |
EPS Diluted (Quarterly) | -0.02 |
Profit Margin (Quarterly) | -4.25K% |
Earnings Yield | -11.56% |
Normalized Earnings Yield | -11.29 |